These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23826311)

  • 21. The proteomics of prostate cancer exosomes.
    Drake RR; Kislinger T
    Expert Rev Proteomics; 2014 Apr; 11(2):167-77. PubMed ID: 24564711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Seminal fluid: a useful source of prostate cancer biomarkers?
    Roberts MJ; Richards RS; Gardiner RA; Selth LA
    Biomark Med; 2015; 9(2):77-80. PubMed ID: 25689895
    [No Abstract]   [Full Text] [Related]  

  • 23. A peptide-centric approach to analyse quantitative proteomics data- an application to prostate cancer biomarker discovery.
    Lima T; Rodrigues JE; Manadas B; Henrique R; Fardilha M; Vitorino R
    J Proteomics; 2023 Feb; 272():104774. PubMed ID: 36427804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of novel candidate urinary protein biomarkers for prostate cancer in a multiethnic cohort of South African patients via label-free mass spectrometry.
    Adeola HA; Soares NC; Paccez JD; Kaestner L; Blackburn JM; Zerbini LF
    Proteomics Clin Appl; 2015 Jun; 9(5-6):597-609. PubMed ID: 25708745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteomic analysis of N-glycosylation of human seminal plasma.
    Yang X; Liu F; Yan Y; Zhou T; Guo Y; Sun G; Zhou Z; Zhang W; Guo X; Sha J
    Proteomics; 2015 Apr; 15(7):1255-8. PubMed ID: 25476145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma metabolomic profile in prostatic intraepithelial neoplasia and prostate cancer and associations with the prostate-specific antigen and the Gleason score.
    Markin PA; Brito A; Moskaleva N; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; La Frano MR; Appolonova SA
    Metabolomics; 2020 Jun; 16(7):74. PubMed ID: 32556743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seminal plasma proteins in prostatic carcinoma: increased nuclear semenogelin I expression is a predictor of biochemical recurrence after radical prostatectomy.
    Izumi K; Li Y; Zheng Y; Gordetsky J; Yao JL; Miyamoto H
    Hum Pathol; 2012 Nov; 43(11):1991-2000. PubMed ID: 22617231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer.
    Kim Y; Ignatchenko V; Yao CQ; Kalatskaya I; Nyalwidhe JO; Lance RS; Gramolini AO; Troyer DA; Stein LD; Boutros PC; Medin JA; Semmes OJ; Drake RR; Kislinger T
    Mol Cell Proteomics; 2012 Dec; 11(12):1870-84. PubMed ID: 22986220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
    IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
    Hendriks RJ; van Oort IM; Schalken JA
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-molecular weight compounds in human seminal plasma as potential biomarkers of male infertility.
    Lazzarino G; Listorti I; Muzii L; Amorini AM; Longo S; Di Stasio E; Caruso G; D'Urso S; Puglia I; Pisani G; Lazzarino G; Tavazzi B; Bilotta P
    Hum Reprod; 2018 Oct; 33(10):1817-1828. PubMed ID: 30239786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extracellular Vesicle Proteome in Prostate Cancer: A Comparative Analysis of Mass Spectrometry Studies.
    Bernardino RMM; Leão R; Henrique R; Pinheiro LC; Kumar P; Suravajhala P; Beck HC; Carvalho AS; Matthiesen R
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical variables.
    Gabriele C; Aracri F; Prestagiacomo LE; Rota MA; Alba S; Tradigo G; Guzzi PH; Cuda G; Damiano R; Veltri P; Gaspari M
    Clin Proteomics; 2023 Nov; 20(1):52. PubMed ID: 37990292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness.
    Ruiz-Plazas X; Rodríguez-Gallego E; Alves M; Altuna-Coy A; Lozano-Bartolomé J; Portero-Otin M; García-Fontgivell JF; Martínez-González S; Segarra J; Chacón MR
    J Transl Med; 2019 Sep; 17(1):307. PubMed ID: 31500625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
    Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
    Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization and evaluation of gene fusions as a measure of genetic instability and disease prognosis in prostate cancer.
    Schimmelpfennig C; Rade M; Füssel S; Löffler D; Blumert C; Bertram C; Borkowetz A; Otto DJ; Puppel SH; Hönscheid P; Sommer U; Baretton GB; Köhl U; Wirth M; Thomas C; Horn F; Kreuz M; Reiche K
    BMC Cancer; 2023 Jun; 23(1):575. PubMed ID: 37349736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens.
    De Marzo AM; Knudsen B; Chan-Tack K; Epstein JI
    Urology; 1999 Apr; 53(4):707-13. PubMed ID: 10197845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants.
    Nguyen EV; Centenera MM; Moldovan M; Das R; Irani S; Vincent AD; Chan H; Horvath LG; Lynn DJ; Daly RJ; Butler LM
    Mol Cell Proteomics; 2018 Aug; 17(8):1470-1486. PubMed ID: 29632047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining prostrate-specific antigen and Gleason score increases the diagnostic power of endorectal coil magnetic resonance imaging in prostate cancer pathological stage.
    Tsao CW; Lin MH; Wu ST; Meng E; Tang SH; Chen HI; Sun GH; Yu DS; Chang SY; Cha TL
    J Chin Med Assoc; 2013 Jan; 76(1):20-4. PubMed ID: 23331777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.